Dr Reddy’s Labs to acquire Progynova brands in $32 Mn India deal
News by Aliceblue News Desk
19 Feb 2026
Introduction
Leading pharmaceutical company acquires Progynova and Cyclo-Progynova trademarks for India from Mercury Pharma Group for USD 32.15 million to enter hormone therapy segment.
Also Read: Zomato parent Eternal inks strategic AI deal with OpenAI for platform upgrade
Share price movement of Dr. Reddy’s Lab
On February 19, 2026, Dr Reddys Laboratories Ltd opened at ₹1,292.70, up 0.91% from its previous close of ₹1,280.85. The stock reached a high of ₹1,297.00 (1.26%) and a low of ₹1,282.90. By 11:36 AM, it traded at ₹1,286.05, up 0.41%, with a market cap of ₹1,07,332.62 crore.
Dr Reddy’s Acquires Progynova Brands
Dr. Reddy’s Laboratories Limited entered a definitive agreement with Mercury Pharma Group Limited to acquire Progynova and Cyclo-Progynova trademarks and related assets for India for USD 32.15 million.
The acquisition covers hormone replacement therapy brands Progynova and Cyclo-Progynova in India. Mercury Pharma Group Limited is not a related party. The transaction does not fall under related party transactions.
Progynova is an estradiol valerate therapy for estrogen deficiency. As per IQVIA MAT December 2025, the brand recorded INR 100 crore sales in India. The deal expands the gynaecology portfolio.
Stock performance of Dr. Reddy’s Lab for period of 1 week, 6 months, and 1 year
Dr Reddys Laboratories Ltd gained 0.42% over the past week, rose 0.21% in six months, and increased 9.82% over the past one year.
Also Read: KNR Constructions bags massive ₹2,163 Cr ECR elevated corridor project
Shareholding pattern of Dr. Reddy’s Lab
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 26.60% | 26.60% | 26.60% |
| FII | 22.30% | 24.70% | 25.30% |
| DII | 41.30% | 38.80% | 37.80% |
| Public | 10% | 9.60% | 10.00% |
| Others | 0.30% | 0.20% | 0.30% |
About Dr. Reddy’s Lab
Dr Reddys Laboratories Ltd (NSE: DRREDDY) is a global pharmaceutical company offering APIs, generics, branded generics, biosimilars, and OTC products across major therapeutic areas worldwide.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Dr Reddys Laboratories Ltd share price rising today?
A: Dr Reddys Laboratories Ltd gained after acquiring Progynova and Cyclo-Progynova trademarks for India from Mercury Pharma Group for USD 32.15 million.
Q: What is Dr Reddys Laboratories Ltd’s main business focus?
A: Dr Reddys Laboratories Ltd develops and sells APIs, generics, branded generics, biosimilars, and OTC products across multiple therapeutic areas globally.
Q: What are the 52-week high and low of Dr Reddys Laboratories Ltd stock?
A: Dr Reddys Laboratories Ltd stock has a 52-week high of ₹1,377.95 and a low of ₹1,025.90.
News Author
Aliceblue News Desk
